Cost–utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan

References

• Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-224
   PubMed Web of Science ®Google Scholar
• Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl 2):30-60
   PubMed Web of Science ®Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
   PubMedGoogle Scholar
• Guidelines for the management of hepatitis C virus infection: first edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013;43:1-34
   PubMed Web of Science ®Google Scholar
• Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International 2011;31:61-80
   PubMed Web of Science ®Google Scholar
• Kanda T, Imazeki F, Azemoto R, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011;56:3335-42
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Stedman C, et al. GS-7977 phase II trials: concordance of SVR4 with SVR12 and SVR24 in HCV genotypes 1-3. Presentation, EASL 18–22 April 2012, Barcelona. Available at: https://www.nice.org.uk/guidance/ta252
   Google Scholar
• Poynard T, Marcellin P, Bissery A, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepatitis 2003;10:197-204
   PubMed Web of Science ®Google Scholar
• [JSH Guidelines for the Management of Hepatitis C Virus Infection]. 2015. Available at: https://www.jsh.or.jp/files/uploads/HCV_GL_ver4_Sept01_final.pdf [Last accessed16 September 2015]
   Google Scholar
• Tanaka A. [JSH guidelines for the management of hepatitis C virus infection (version 3)]. Nihon Rinsho Japan J Clin Med 2015;73:221-7
   PubMedGoogle Scholar
• Drenth JP. HCV treatment – no more room for interferonologists? N Engl J Med 2013;368:1931-2
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
   PubMed Web of Science ®Google Scholar
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-210
   PubMed Web of Science ®Google Scholar
• Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015;22:882-9
   PubMed Web of Science ®Google Scholar
• Fukuda TST, Ikeda S, Igarashi A, et al. [Guideline for economic evaluation of healthcare technologies in Japan]. J Natk Inst Public Health 2013;62:625-40
   Google Scholar
• Telavic PMS interim report. 2014. Available at: http://medical.mt-pharma.co.jp/intro/tlv/investigation/pdf/tlv-zenrei201409.pdf [Last accessed 16 September 2015]
   Google Scholar
• Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: the CONCERTO-4 study. Hepatol Res 2015;45:501-13
   PubMed Web of Science ®Google Scholar
• JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol Res 2014;44(Suppl S1):59-70
   Google Scholar
• Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012;19:e134-42.w20
   PubMed Web of Science ®Google Scholar
• Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Experimental Med 2008;215:33-42
   PubMed Web of Science ®Google Scholar
• Ishida H, Yotsuyanagi H. [Study of the cost-effectiveness of the standard treatment for chronic hepatitis C]. Ministry of Health Labour and Welfare grants system. Available at: https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do? resrchNum=201333004B [Last accessed 16 September 2015]
   Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7
   PubMed Web of Science ®Google Scholar
• Statistics Bureau of the Ministry of Internal Affairs and Communication. Table 2-35 Complete Life Table (1891N2000) 25/06/2015. Statistics Bureau of the Ministry of Internal Affairs and Communication. Avilable at: http://www.stat.go.jp/data/chouki/02.htm [Last accessed 25/ 06/2015]
   Google Scholar
• Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012;15(1 Suppl):S65-S71
   PubMed Web of Science ®Google Scholar
• Sugimori H. [Study of utility for hepatitis]. Ministry of Health Labour and Welfare grants system. Available at: https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
   Google Scholar
• Gilead Sciences. Health State Utilities for HCV (SF6D). 2014
   Google Scholar
• National Institute for Health and Care Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C – NICE technology appraisal guidance 252. 2012. Available at: guidance.nice.org.uk/ta252 [Last accessed 18 June 2012]
   Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
   Web of Science ®Google Scholar
• 2015 National Drug Tariff. Ministry of Health, Labour and Welfare. Available at: http://www.mhlw.go.jp/topics/2014/03/tp0305-01.html [Last accessed 15 September 2015]., 2015
   Google Scholar
• Ikeda T. [Medical expenses for the viral liver diseases]. Ministry of Health Labour and Welfare grants system. Available at: https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
   Google Scholar
• Ishida H. [Study of the cost-effectiveness of the standard treatment for chronic hepatitis C]. Ministry of Health Labour and Welfare grants system. Available at: https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. 2006, Oxford University Press.
   Google Scholar
• Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states: more money for severer health states? Cost Effectiveness Resource Allocation 2013;11:22
   PubMedGoogle Scholar
• Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397-406
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544-63
   PubMed Web of Science ®Google Scholar
• Curry MP, Bacon B, Dieterich D, et al. Effectiveness of 8 or 12 week LDV-SOF in treatment-naïve patients with non-cirrhotic, genotype 1 hepatitis C: real-world experience from the TRIO Network. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA
   Google Scholar
• Curry MP, Bacon B, Dieterich D, et al. Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 hepatitis C: real-world experience from the TRIO Network. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA
   Google Scholar
• Terrault N, Zeuzem S, Di Bisceglie AM, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA
   Google Scholar